Best 2-Decade Total Return Stocks
« Back to slide 1
Continue to slide 3 »

#9. Gilead Sciences Inc (GILD) — $10K BECAME $605,159.10

Company Name:  Gilead Sciences Inc
Sector:  Biotechnology
Growth of $10,000.00
With Dividends Reinvested Into GILD

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include HIV/AIDS, liver diseases, hematology/oncology and inflammation/respiratory diseases. Co.'s products include Biktarvy for the treatment of HIV-1 infection in certain patients, Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease, Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, and Letairis® (ambrisentan) for the treatment of pulmonary arterial hypertension.

« Back to slide 1
Continue to slide 3 »
GILD 20-Year Return
Start date: 12/15/1999
End date: 12/13/2019
Start price/share: $1.24
End price/share: $65.77
Starting shares: 8,064.52
Ending shares: 9,205.64
Dividends reinvested/share: $10.01
Total return: 5,954.55%
Average Annual Total Return: 22.76%
Starting investment: $10,000.00
Ending investment: $605,159.10

Presented with the assumption of reinvestment of any dividends on ex-date; historical stock values are shown adjusted for any subsequent splits.
Investing Slideshows
Wise & Famous Investing Quotes
20 Largest Companies In The USA
21 Growth Stocks For 2021
10 Dividend Leaders Ready To Run
Best 5-Year Total Return Stocks
Best 10-Year Total Return Stocks
Best 2-Decade Total Return Stocks
GILD — Current Quote
Quotes delayed 20 minutes
Get Free SEC filing alerts for GILD:
GILD SEC Filing Email Alerts ServiceExternal link
 

Best 2-Decade Total Return Stocks - Page 2 | www.RediNews.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in RediNews.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video.